SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by AspenBio Pharma, Inc. on November 18, 2008. The registrant is a Colorado-based company focused on developing diagnostic tests. Note: The request metadata referenced "Riot Platforms, Inc."; however, the provided filing text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a Current Report regarding a specific corporate event and does not contain financial statements.
Material Changes and Events
- Item 8.01 (Other Events): On November 18, 2008, the company issued a press release regarding progress on its FDA 510(k) clinical trial for AppyScore.
- Product Focus: AppyScore is described as the world's first blood-based diagnostic test for human appendicitis.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a detailed risk factor section. The primary focus is the regulatory milestone of the clinical trial progress for the AppyScore diagnostic test.
Investor Verification Checklist
- Verify the current status of the FDA 510(k) clearance for the AppyScore test.
- Review the attached Exhibit 99.1 (Press Release) for specific clinical trial data points not summarized in the 8-K body.
- Confirm the company's cash runway and funding status, as this filing does not disclose liquidity metrics.
- Clarify the discrepancy between the requested company name (Riot Platforms) and the actual filing registrant (AspenBio Pharma).